Current pharmacotherapeutic strategies for overactive bladder

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 7, 2002, Pages 827-833

  Garely, Alan D ^a   Burrows, Lara J ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Antimuscarinic drugs; Overactive bladder; Oxybutynin chloride; Tolterodine tartrate; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DULOXETINE; IMIPRAMINE; OXYBUTYNIN; PLACEBO; PROPIVERINE; RESINIFERATOXIN; TOLTERODINE; TROSPIUM CHLORIDE; BENZHYDRYL DERIVATIVE; CRESOL; MANDELIC ACID DERIVATIVE; PHENYLPROPANOLAMINE;

AGE; BLADDER DISEASE; CARDAMOM; CELERY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOMESTICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TOLERABILITY; GENDER; HUMAN; INCIDENCE; MICTURITION DISORDER; OCCUPATION; OVERACTIVE BLADDER; PHYSICAL ACTIVITY; PREVALENCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SOCIAL ASPECT; SOMNOLENCE; SYMPTOMATOLOGY; URGE INCONTINENCE; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA; DELAYED RELEASE FORMULATION; URINE INCONTINENCE;

BENZHYDRYL COMPOUNDS; CHOLINERGIC ANTAGONISTS; CRESOLS; DELAYED-ACTION PREPARATIONS; HUMAN; MANDELIC ACIDS; QUALITY OF LIFE; URINARY INCONTINENCE; URINATION DISORDERS; HUMANS; PHENYLPROPANOLAMINE;

EID: 0035987546     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.7.827     Document Type: Review

References (66)

1. Definition of overactive bladder and epidemiology of urinary incontinence
2. Epidemiology, pathophysiology, and evaluation of urinary incontinence and overactive bladder
3. How widespread are the symptoms of an overactive bladder and how do we manage them? A population-based prevalence study
4. The overactive bladder: An overview for primary care health providers
5. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder
6. Pharmacological treatment of urinary incontinence
7. The mechanism of action of tolterodine
8. The patient with an overactive bladder - Symptoms and quality of life issues
9. Overactive bladder significantly affects quality of life
10. Health-related quality of life among adults with symptoms of overactive bladder: Results from a US community-based survey
11. Urinary incontinence in adults: Acute and chronic management
12. The clinical efficacy of oxybutynin
13. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability
14. Tolterodine - A new bladder selective antimuscarinic agent
15. Muscarinic receptor antagonists in the treatment of overactive bladder
16. The mechanism of action of tolterodine
17. Oxybutinin: A new drug with analgesic and anticholinergic properties
18. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance
19. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder
20. Extended-release oxybutynin
21. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin
22. Once daily controlled versus immediate release oxybutynin chloride for urge incontinence
23. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence
24. Topical administration of oxybutynin hydrochloride in women with urge incontinence: Results of a prospective randomized double-blind study
25. Treatment of overactive bladder with modified intravesical oxybutynin chloride
26. Transdermal oxybutynin: A multi-centre, prospective, randomised, double-blind, placebo-controlled study in adults with urge urinary incontinence
27. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity
28. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
29. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
30. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
31. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine
32. Twelve-month treatment of overactive bladder. Efficacy and tolerability of tolterodine
33. Treatment of overactive bladder: Long-term tolerability and efficacy of tolterodine
34. Idiopathic bladder hyperactivity and ditropan: An efficacy and compliance issue
35. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder
36. Prospective randomised controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study
37. Medical treatment of overactive bladder
38. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate
39. Tolterodine once daily: Selectivity for the bladder over effects on salivation compared to Ditropan XL
40. Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomized, double-blind, multicentre clinical trial
41. Trospium chloride in patients with motor urge syndrome (detrusor instability): A double-blind, randomised, multicentre, placebo-controlled study
42. Clinical trial to evaluate trospium chloride (Uraplex) effectiveness and tolerance in patients with detrusor instability incontinence and its impact on quality of life
43. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic)
44. A placebo-controlled multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence
45. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence: A multicentre dose-optimizing study
46. Clinical effect of propiverine in patients with urge or stress incontinence
47. Muscarinic receptor antagonists in the treatment of overactive bladder
48. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neutral control of lower urinary tract function in the chloralose-anesthetized female cat
49. Duloxetine shows efficacy for stress urinary incontinence
50. Treatment of overactive bladder: Other drug mechanisms
51. Double-blind study of impramine and placebo for incontinence due to bladder instability
52. Intravesical capsaicin in neurologically impaired patients with detrusor hyperreflexia
53. Intravesical capsaicin and resiniferatoxin therapy: Spicing up the ways to treat overactive bladder
54. Should we be using chili pepper extracts to treat the overactive bladder?
55. Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: A new alternative to medical and surgical procedures?
56. Overactive bladder: Special considerations in the geriatric population
57. Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial
58. Tolterodine: A safe and effective treatment for older patients with overactive bladder
59. Randomized, double-blind study to compare extended-release oxybutynin and tolterodine for overactive bladder
60. Enhancing patient compliance in the elderly: Role of packaging aids and monitoring
61. Electrophysiological evaluation of potential adverse effects of tolterodine, oxybutynin and trospium chloride on the central nervous system
62. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride
63. Explicit criteria for determining potentially inappropriate medication use by the elderly
64. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity
65. Tolterodine: An effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms
66. Efficacy and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients